Table 1.

Baseline characteristics of the cohort of ranitidine and famotidine users.

Characteristics	Ranitidine (n = 88,416)	Famotidine (n = 10,129)
Male (n, %)	43,217 (48.9)	5307 (52.4)
Age (years, mean ± SD)	61.0 ± 11.3	59.8 ± 11.8
30–49 (years, n, %)	14,305 (16.2)	1966 (19.4)
50–59 (years, n, %)	23,356 (26.4)	2810 (27.7)
60–69 (years, n, %)	26,914 (30.4)	2850 (28.2)
70–79 (years, n, %)	23,841 (27.0)	2503 (24.7)
Diabetes mellitus	32,051 (36.3)	3501 (34.6)
Diabetes mellitus period
≤3 years	9529 (10.8)	1006 (9.9)
≥4 years	22,522 (25.5)	2495 (24.6)
Dosage
mg, (mean ± SD)	204,919 ± 104,366	29,579 ± 15,544
DDD (mean ± SD)	683.1 ± 347.9	739.5 ± 388.6
Cumulative duration
12–17 months	40,557 (45.9)	4023 (39.7)
18–23 months	19,361 (21.9)	2133 (21.0)
24–29 months	11,126 (12.6)	1364 (13.5)
≥30 months	17,372 (19.6)	2609 (25.8)

DDD, Defined daily dose.